

Drug Highlight – April 2016

FDA Drug Approvals

Each month the FDA approves new medications, and below is a highlight of the most relevant new approvals and/or drugs which have the potential to impact your prescription plan. While the medications below have been evaluated and approved by the FDA, they may not enter the marketplace for several weeks or months. Therefore, pricing information for these medications is typically unavailable at the time of approval.

New Brand Approvals			
Drug Name	Uses/Treatment	Pricing Information	Other Information
Taltz® (ixekizumab) injection	Treatment for moderate to severe plaque psoriasis in adults	Pricing information not yet available	<ul style="list-style-type: none"> • Drug Information: ixekizumab is a subcutaneous (just under the skin) injection in a single-dose prefilled syringe or auto-injector. After a dose titration ixekizumab is dosed at one syringe every 4 weeks • Formulary Management: Considered non-preferred upon market entry. • BIC SpecialtyRx: Comprehensive clinical management and competitive discounts via MedTrak's BIC Specialty Pharmacy Network. • Control Trak: Subject to Max Dollar and Max Dose edits.
Defitelio® (defibrotide) injection	Treatment for hepatic veno-occlusive disease (VOD) with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT) in adults and children	Pricing information not yet available	<ul style="list-style-type: none"> • Drug Information: defibrotide is given every 6 hours as a 2-hour IV infusion. Patients are treated for a minimum of 21 days. If patient does not show signs of VOD resolution, treatment should continue until resolution occurs. • Formulary Management: Considered non-preferred upon market entry. • BIC SpecialtyRx: Comprehensive clinical management and competitive discounts via MedTrak's BIC Specialty Pharmacy Network • Control Trak: Subject to Max Dollar and Max Dose edits.
Cambia® (Diclofenac Potassium) powder for oral solution	Treatment for acute migraine attacks with or without aura in adults	Varies based on number of migraines per month; \$60 per dose	<ul style="list-style-type: none"> • Drug Information: Cambia is a powdered formulation of diclofenac that is mixed into 1-2 ounces or 2-4 tablespoons of water. Repeat doses are not recommended. Diclofenac is a non-steroidal anti-inflammatory (NSAID) which is also available in tablet, capsule, and topical formulations • Formulary Management: Considered non-preferred upon market entry. • Control Trak: Subject to Max Dollar and Max Dose edits.

The Clinical Care Center (CCC) is MedTrakRx's comprehensive clinical solution to control costs and increase adherence for our Clients and Members. The Clinical Care Center is made up of 7 Steps to Improved Outcomes: Generics Plus, Formulary Management, Member & Client Education, RightChoice, Control Trak, Best-In-Class (BIC) SpecialtyRx, and Clinical Concierge.